As rapidly developing patient-derived xenografts (PDX) could represent potential sources of cancer stem cells (CSC), we selected and characterized non-cultured PDX cell suspensions from four different renal carcinomas (RCC). Only the cell suspensions from the serial xenografts (PDX-1 and PDX-2) of an undifferentiated RCC (RCC-41) adapted to the selective CSC medium. The cell suspension derived from the original tumor specimen (RCC-41-P-0) did not adapt to the selective medium and strongly expressed CSC-like markers (CD133 and CD105) together with the non-CSC tumor marker E-cadherin. In comparison, PDX
INTRODUCTION
Current knowledge indicates that the initiation, growth, metastasis, chemo-resistance and recurrence of cancers are driven by a subset of cells endowed with stem-like properties called cancer stem cells (CSCs) or tumor-initiating cells. These cells are defined by their capability to self-renew and to recapitulate tumor formation when injected in mice [1] [2] [3] . Therefore, the identification of CSCs and a better understanding of their complex characteristics will provide very important diagnostic, therapeutic and prognostic targets for clinical application [1, 2] .
Renal clear cell carcinoma (RCC) is a very aggressive cancer resistant to conventional chemo-and radiotherapy with an early metastatic evolution [4] , and it seems likely that renal CSCs may have a relevant role in tumor establishment, progression, and recurrence [5] . At present, only few reports have investigated the presence of CSCs in renal carcinoma. In this context, recent histochemistry observations illustrate that the human prominin-1 (CD133) antigen, in particular of the AC133 epitope frequently employed to isolate CSCs from different tumors [6] , does not seem a reliable CSC marker in RCC [7, 8] . Some groups attempted to identify renal CSCs using functional assays such as the ability to form spheres in serum-free medium [9] or the presence of the so-called Side Population [10] . Following an alternative sorting strategy, our group has recently identified, from different human RCC specimens a small subset of CSCs cells expressing the mesenchymal marker CD105 [11] [12] [13] . However, further immunohistochemistry studies on 102 RCC biopsies have shown that CD105 staining could only be detected in the cytoplasm of isolated tumor cells in the specimens derived from patients with high tumor grade and at the highest tumor stage [14] . Finally, it has been demonstrated that tumor-initiating cell frequencies were remarkably rare in well-differentiated tumors [15] [16] [17] whereas cancers in which differentiation programs are impaired would be comprised of only cells with stem and progenitor cell phenotypes [18, 19] . Overall, the abovementioned data suggest that the current understanding of the renal stem cell system is not complete and that the kidney cancer could harbor different CSC pools displaying different phenotypes and functions according likely to tumor grade, stage and differentiation [14, 19] . Thus, it is of major interest to develop new approaches in order to identify new putative renal CSCs subsets.
In these studies, we developed an alternative strategy for identifying renal CSCs by adapting to in vitro culture, primary cell suspensions from serial Patient-Derived Xenografts (PDX). Of note, PDX were obtained by serially grafting tumor samples characterized according to their different degrees of differentiation, tumor stage, and aggressiveness in SCID mice [19] . Cell suspensions from PDX of four different RCC patients, characterized by the shortest latency for tumor formation in SCID mice, were chosen from the Gustave Roussy Institute cell collection. The above-mentioned cell suspensions had been immediately frozen without in vitro culture (P-0) or after few in vitro passages (P-1; P-3), representing therefore invaluable material for this type of study [19] . Only the PDX cell suspension from one (RCC-41) out of four patients was able to adapt to the selective medium growth conditions. RCC-41 is an undifferentiated RCC, and from its serial xenografts (RCC-41-PDX-1 and RCC-41-PDX-2) we isolated, sorted, and cloned three novel renal CSCs subsets that diverge from each other in phenotypic and functional properties, fulfilling however most of the criteria used to identify CSCs. These data indicate that even using PDX model, which has been reported as a necessary step for the successful isolation of renal CSCs from Wilm's xenograft [20] , it is very difficult to purify CSCs from RCC. Nevertheless, our data strengthen the idea that RCC carcinomas harbor different CSC pools displaying different phenotype and functions. In addition, the serial PDX derived from a single tumor may help to unmask different CSC subsets potentially expressed by a single RCC during its in vivo progression, or to generate ex novo different CSC-like subsets.
RESULTS

In vitro selection of RCC cell suspensions derived from primary RCC xenografts in SCID mice
To test the hypothesis that patient-derived xenografts [18] could represent a source of CSCs in renal cell carcinoma, we employed never cultured or firstpassage cell suspensions derived from four primary RCC xenografts. These PDXs (RCC-28-PDX-1 and -PDX-2, RCC-17-PDX-1 and -PDX-2, RCC-41-PDX-1 and -PDX-2, and RCC-47-PDX-1 and -PDX-2) characterized by different tumor stage, differentiation, histopathology and in vivo aggressiveness [19] (Table 1) , were cultured in vitro with a selective medium (DMEM-LG) designed to preserve CSC stemness properties [12] . Only two cell suspensions out of eight (RCC-41-PDX-1 and -PDX-2) adapted to the selective medium and could be serially sub-cultured (Table 1) . Cryopreserved cell suspensions were seeded at vessels of human origin with CSC displaying peri-vascular distribution. By contrast, RCC-41-PDX-2 originated tumors exhibiting only vessels of mouse origin without CSC peri-vascular distribution.
Altogether, our results indicate that PDX murine microenvironment promotes a continuous redesign of CSC phenotype, unmasking CSC subsets potentially present in a single RCC or generating ex novo different CSC-like subsets. www.impactjournals.com/oncotarget 5 × 10 5 cells per 25 cm 2 flask. RCC-41-PDX-1 and -PDX-2 cells adhered to the plastic surface with an efficiency of about 40%. After two weeks, RCC-41-PDX-1 and -PDX-2 cells started to proliferate forming isolated colonies exhibiting epithelioid morphology. Upon subculture, about 80% of RCC-41-PDX-1 and -PDX-2 cells adhered to the plastic surface, started to proliferate, and could be serially sub-cultured. Interestingly, the P-0 cell suspension derived from the original tumor (RCC-41-P-0) adapted to DMEM-LG medium but subsequently could not be serially passaged.
Phenotype of RCC-41-P-0 versus RCC-41-PDX-1 and RCC-41-PDX-2
Flow cytometry analysis of primary RCC-41-P-0 cells shows that the majority of these cells strongly express two CSC stem-like markers: CD133 and CD105, while nearly 50% express E-cadherin ( Figure 1A ). The expression of E-cadherin in RCC is a good prognostic marker that indicates a tendency towards differentiation [21] . CSCs do not express differentiation markers [1] [2] [3] , therefore the expression of E-cadherin suggests the persistence of a non-CSC cell fraction [12, 13] in the RCC-41-P-0 cell suspension.
Interestingly, PDX-1 and PDX-2 cell suspensions underwent a phenotypic evolution since PDX-1 displays a CD133 + /CD105
-/E-cad low phenotype and PDX-2 a CD133 low /CD105
-/E-cad -phenotype. These data suggest that RCC-41-PDX-1 and -PDX-2 cell suspensions could represent a mixture of CSC-like and non-CSC tumor cells. We therefore investigated the expression of additional CSC and non-CSC markers. Further phenotypic analyses ( Figure 1B-1C) show that PDX-1 and PDX-2 share the expression of additional CSC markers such as CD29, CD146, OCT3/4, Nanog, and Nestin [22] [23] [24] . In contrast, they diverged in the expression of other markers displaying a bimodal distribution such as CD132 (in PDX-1, Figure 1C ) and EpCAM (PDX-2, Figure 1B) . EpCAM is an epithelial surface molecule whose expression in RCC is an independent predictor associated with improved survival [25] , while in several cancers, EpCAM is considered as a progression/CSC marker [26] . CD132 (common gamma chain) is a cytokine receptor sub-unit expressed by normal tubular epithelial cells [27, 28] and renal CSC-CD105 + [11] , whose loss characterizes both in vitro and in vivo non-CSC RCC cells [27, 28] .
Cell sorting and characterization of RCC-41-PDX-1 and -PDX-2 subsets
The above-mentioned results indicate that RCC-41-PDX-1 and -PDX-2 express both CSC and non-CSC markers. Therefore, we decided to enrich the CSC component by cell sorting. In RCC-41-PDX-1 cultures, we sorted to eliminate the CD132-negative cells, which likely represent the non-CSC fraction [11, 27, 28] , and selected the CD132-positive cells, which could represent a CSC-like subset [11, 24, 27] . In RCC-41-PDX-2 cultures, RCC-41-PDX-2/CD133
-and RCC-41-PDX-2/CD133 + were sorted on the basis of CD133 expression. Subsequently, these sorted PDX-1 and PDX-2 subsets were cloned at limiting dilution and different clones were derived.
Flow cytometry analysis shows that sorted RCC-41-PDX-1 cells expressed CD132 as a single homogeneous peak, associated with low but detectable levels of CD133, OCT3/4 and NANOG, and no expression of EpCAM (Figure 2A ). Sorted RCC-41-PDX-2/CD133 -and RCC-41-PDX-2/CD133 + ( Figure 2B ) shared the expression of equivalent high levels of OCT3/4, NANOG but they obviously differed in the expression of CD133 and EpCAM. This latter one was very faintly expressed in RCC-41-PDX-2/CD133 -cells and well expressed in RCC-41-PDX-2/CD133 + cells.
In vitro CSC functional properties of RCC-41-PDX-1 and -PDX-2 subsets
CSCs are more resistant to conventional chemotherapy than differentiated cancer cells. Indeed, CSCs employ several mechanisms to protect themselves against cytotoxic agents. For example, they have high levels of activity of the detoxifying enzymes ALDH, which enable them to resist the effects of chemotherapy [29] . Therefore, we measured the ALDH activity in RCC-41 by flow cytometry, using an ALDEFLUOR kit. As -displayed high ALDH activity (> 80% positive cells) ( Figure 3A) . We also investigated in the PDX-1 and PDX-2 CSC clones the presence of the most primitive cells (Side Population, SP) able to extrude the Vybrant violet dye. The experiments were performed in the presence or not of the transporter inhibitor Verapamil: no SP population could be detected in PDX-1 or PDX-2 CSC clones and PDX-1 and PDX-2 clones did not show significant phenotypic differences (data not shown). A remarkable feature of CSCs is their capability of self-renewal. Indeed this mechanism is required for preservation of the CSC pool [1] [2] [3] . In order to test their in vitro self-renewal potential, sorted RCC-
41-PDX-1/CD132
+ and unsorted RCC-41-PDX-2 cells were cultured at concentrations ranging from 10 2 to 1 cell per well in DMEM-LG serum-free medium and assessed for spheroid formation ( Figure 3B + and RCC-41-PDX-2/CD133 -were plated in the absence of serum at a density of 1 to 10 cells per well in 24-well plates containing DMEM-LG medium. After 2 weeks, each well was examined under a light microscope, and the total number of wells with colonies was determined. Data represent mean values of three replicates for three experiments; error bars correspond to 95% confidence intervals. www.impactjournals.com/oncotarget RCC-41-PDX-2/CD133 + formed spheroids with respective efficiencies of 6, 3, and 1% ( Figures 3B and 3C) . RCC-41-PDX-1/CD132 + and -PDX-2 primary spheroids were subsequently dissociated using trypsin and were able to grow serially as spheroids at their respective limiting dilutions.
Another known CSC property is the capacity to form adherent colonies at limiting dilution in serum-free medium [2, 3] . Figure 3D shows that RCC-41-PDX-1/ CD132 + and RCC-41-PDX-2/CD133 -exhibit high cloning efficiency (60% and 40% respectively), while RCC-41-PDX-2/CD133 + display a lower cloning efficiency (5%).
Differential expression of the multipotency gene ERBB4 and of tumor suppressor genes in CD133-negative versus CD133-positive RCC41-PDX-2 cells
To better understand the growing advantage of RCC41-PDX-2/CD133
-cells over the RCC41-PDX-2/ CD133 + cells, we performed microarray analysis. 486 genes were differentially expressed with more than 2-fold change and an adjusted p-value of 0.05 ( Figure 4A ). Among them, 63 genes were up-regulated and 423 were down-regulated in RCC-41-PDX-2/CD133
− versus RCC-41-PDX-2/CD133 + . We first analyzed genes encoding cell surface molecules and found that CD133 -cells overexpressed the EGFR family member ERBB4 as compared to CD133 + cells, which was confirmed by qPCR (more than 20 fold) ( Figure 4B ). The other family members of the ERBB receptors (ERBB1, ERBB2, ERBB3) were not differentially expressed, suggesting a selective up-regulation of ERBB4 ( Figure 4B ). Interestingly, CD133
+ cells displayed by RT-qPCR an increased expression for potential tumor suppressor genes such as INHBA [30, 31] , DIRAS3 [32] , S100A14 [33, 34] , GPR56 [35] [35] , SPINT2 [36, 37] , RNF43 [21, 22, [38] [39] [40] , MT1G [23] [24] [25] 41] , TAGLN [42] [26, 42] , CAV2 [43, 44] ( Figure 4C ). Among these genes, INHBA [30] , MT1G [41] and SPINT2 [37] were reported to have tumor suppressive functions in renal cancers. As well, ANXA3, whose decrease was associated with renal cancer development, was also augmented [45] . The pro-apoptotic gene CASP4 [46] was also found to be up-regulated ( Figure 4C ).
Tumorigenic potential of human renal RCC-41-PDX-1/CD132 + in SCID mice
The results depicted in Table 2 shows that subcutaneous injection of shows a homogenous histopathology consisting of highly mitotic undifferentiated carcinomas, and rare clear cells ( Figure 5B ). Co-staining with anti-hCD31 and antihCD133 antibodies shows that several vessels of human origin are detectable in the serial xenografts ( Figure 5B ) and that CD133 + cells display a peri-vascular distribution ( Figure 5B ) that is maintained in the serial xenografts even if their frequency progressively decreases. In serial xenografts starting from PDX-1.1, we observed the appearance of cells expressing the human epithelial marker EpCAM (Figure 5B ), which strongly increases in PDX-1.2, suggesting a natural tendency towards epithelial differentiation, that is associated with a rarefied frequency of CD133 + cells ( Figure 5A and 5B). Thus, RCC-41-PDX-1/CD132 + cells are able to generate serially transplantable tumors in SCID mice, which recapitulate the histopathology of the original RCC and show a tendency for a progressive engagement in an epithelial differentiation pathway. This was confirmed by the increased expression of E-cadherin and the decreased expression of vimentin analyzed by RT-qPCR ( Figure 5C ). Interestingly, flow cytometry analysis performed on 
Tumorigenic potential of human renal unsorted RCC-41-PDX-2 and RCC-41-PDX-2 subsets in SCID Mice
Subcutaneous injection of 10 3 and 10 2 RCC-41-PDX-2 and RCC-41-PDX-2/CD133 -cells into SCID mice generated tumors within 3 weeks (n = 4) ( Table 3 and Figure 6A and 6B). RCC-41-PDX-2-generated tumors grew twice as fast as RCC-41-PDX-2/CD133 -tumors in a statistically significant way ( Figure 6A and 6B) . Indeed, RCC41-PDX-2-injected mice developed large tumors (1500 mm 3 ) within 4 weeks of injection whereas mice engrafted with RCC41-PDX-2/CD133 -cells reached this volume after 8 weeks ( Figure 6A and 6B) . By contrast, RCC-41-PDX-2/CD133 + subset exhibited a consistent reduced tumor forming efficiency as compared to RCC41-PDX-2 and RCC-41-PDX-2/CD133 -. Indeed, RCC-41-PDX-2/ CD133 + formed smaller palpable tumors (100 mm 3 ) detected in the injected mice after 9 weeks and only at the concentration of 10 3 cells per mouse ( Figure 6 ). This differential tumor growth was statistically significant, and indicated that the RCC41-PDX-2/CD133 -subset displays a higher tumorigenic potential than the CD133 + subset.
Loss of human endothelial micro-vessels (EM) in RCC-41-PDX-2 tumors
H&E staining of tumors generated in SCID mice by RCC-41-PDX-2, and RCC-41-PDX-2/CD133 -, RCC-41-PDX-2/CD133 + and their respective clones, shows that PDX-2 xenografts exhibit histopathology similar to that observed in PDX-1 tumors, consisting of highly mitotic undifferentiated carcinomas, and rare clear cells ( Figure 7A ). Immunofluorescence analysis of tumor vessels shows off a remarkable property that distinguishes RCC-41-PDX-1/CD132
+ from RCC-41-PDX-2 xenografts: in all PDX-2 xenografts, vessels are entirely of murine origin as shown by EM counts using hCD31 and mCD34 mAbs proved to be rigorously species-specific in a previous study [47] . All vessels present in PDX-2 xenografts were lined with mCD34 + endothelial cells, whereas vessels lined with hCD31 + endothelial cells were never detected ( Figure 7A ). Moreover PDX-2/CSCs, identified in vivo through the expression of CD146, were detected nearby murine vessels but did not show the strict peri-vascular distribution detected in PDX-1 xenografts ( Figure 7B ).
DISCUSSION
The identification of renal CSCs represents a therapeutic priority that, for the moment, remains somewhat elusive due to RCC genetic and histological heterogeneity [4, 5] . Recently, a CSC population expressing CD105 was purified from RCC patients [12] . An immunohistochemical study, performed on paraffin-embedded tumor samples derived from 102 RCC patients, showed that CD105 expression in tumor cells was found in high-grade tumors and highest tumor stages [14] . This would suggest that RCC may harbor CSCs with different phenotypes [5] . Thus we developed an alternative strategy for identifying putative renal CSCs, different from the CD105 + cell sorting [12] . For this purpose, we exploited the Gustave Roussy Institute cell bank; using never-cultured cell suspensions derived from the four more aggressive serial RCC-PDX displaying different phenotypes, tumor stage and grade [19, 48] . Only RCC-41-PDX-1 and -PDX-2 cell suspensions out of four different RCC-PDX adapted to the selective medium conceived for preserving in vitro the stem cell properties [12] . Interestingly, we also tried to culture the primary cell suspension derived from the original tumor (RCC-41-P-0); however, while the cells attached and grew slowly up to near confluence, they could not be further passaged.
Comparison of the phenotype of RCC41-P-0, RCC-41-PDX-1 and RCC-41-PDX-2 primary cultures showed major phenotypic differences. Indeed, RCC-41-P-0 cells expressed a CD133 The unusual high expression of the stemness markers CD133 and CD105 is probably related to the fact that RCC-41 is an undifferentiated tumor [48] and points out the likely existence in RCC-41-P-0 of a large proportion of very primitive CSC-like cells, while the expression of E-cadherin supports the presence of differentiated non-CSC tumor cells [21, 49, 50] . The sorted CSC/PDX-1 and CSC/PDX-2 subsets, as well as their respective clones, display properties typical of CSCs detected in other solid tumors. Namely they: 1) express stem cell markers, 2) exhibit clonal growth at limiting dilution, 3) grow and can be serially transferred as floating spheroids, 4) express mid-high levels of the detoxifying enzyme ALDH, a typical CSC marker [51] , and 5) generate serially transplantable tumors characterized by similar histopathology. However it must be stated that serial PDX-1/CD132 + xenografts displayed microvessels of human origin and strict peri-vascular distribution of CSCs that favors the preservation of stemness [52] , while PDX-2 xenografts exhibited microvessels of murine origin without perivascular distribution of CSCs.
In addition, between PDX-1/CD132 + - Finally, in PDX-2 xenografts, murine microenvironment induces a remodeling of the CSC properties favoring the appearance of two novel subsets of less primitive CSC since they have lost the potential to generate human microvessels and are characterized by different phenotypes: PDX-2/CD133 -/EpCAM -/ERBB4 + is the predominant aggressive subset while the PDX-2/ CD133 + /EpCAM bright is a minor, less aggressive CSC subset characterized by the expression of several tumor suppressor genes.
In conclusion, our data support the idea that the serial PDX derived from a single tumor may help to unmask the different CSC subsets potentially expressed by a single RCC during its in vivo progression. Alternatively, it is also possible to postulate that the PDX CSC niche, which is of murine origin, could redesign the properties of human CSC favoring the generation of modified CSCs that become unable to generate human microvessels hampering somehow the development of targeted anti-angiogenic preclinical approaches. formation of unsorted RCC-41-PDX-2, and sorted RCC-41-PDX-2 
MATERIALS AND METHODS
Cell culture
Cell suspensions from 4 different RCC-PDX xenografts (RCC-17-PDX-1 and -PDX-2, RCC-28-PDX-1 and -PDX-2, RCC-41-PDX-1 and -PDX-2, RCC-47-PDX-1 and -PDX-2) that resulted in tumor development in SCID mice [19] and RCC-41-P-0 were adapted to in vitro culture using a multipotent adult progenitor cell medium consisting of DMEM-LG (Invitrogen, Paisly, UK) with insulintransferrin selenium 1x (Invitrogen, Paisley, UK), 10 -9 M dexamethasone, 100 U penicillin, 1000 U streptomycin, 10 ng/ml epidermal growth factor (EGF) (Sigma-Aldrich) and 5% FCS (Euro Clone, Wetherby, UK). Adherent cells were maintained in complete DMEM-LG for more than 30 passages, with no change in the expression of stem cell markers as determined by FACS analysis. All other antibodies used for cytofluorimetric analyses (FACS) were directly conjugated with FITC, PE, or APC: anti-CD31, antiCD-146/Muc-18, anti-CD29, anti-CD105, and anti-CD133 monoclonal antibodies (mAbs) (all from Miltenyi Biotec, Cologne, Germany); mAb anti-EpCAM (Biolegend, San Diego, CA). Isotypematched FITC-, PE-, or APC-conjugated control mouse G (IgG) were from Miltenyi.
Antibodies, cytokines, and reagents
Sphere formation assay
We evaluated the self-renewal capacity of RCC-41-PDX-1/CD132 + , RCC-41-PDX-2, RCC-41-PDX-2/ CD133 + , and RCC-41-PDX-2/CD133 -by performing a limiting dilution assay for spheroid formation. Cells were plated using a FACS DiVa cell sorter equipped with autoclone software (Beckton Dickinson, Le Pont-de-Claix, France) at a density of one and 100 cells per well in ultralow attachment 96-well plates (Corning Life Sciences, Acton, MA). Each well was supplemented with 200 μl of serum-free complete DMEM-LG. After 3 weeks, each well was examined under a light microscope and the total number of wells containing spheroid colonies was determined. Five replicates were used for each condition, and the experiment was repeated two times.
RNA extraction and quantitative real time reverse transcriptase polymerase chain reaction
Total RNA was isolated from cells using TRIZOL reagent (Invitrogen), according to manufacturer's instructions. RNA was quantified spectrophotometrically (Nanodrop ND-1000, Wilmington DE). Primers used for qRT-PCR are shown in Table 4 ; other primer sequences are available upon request.
To detect mRNA expression, first-strand cDNA was produced from 200 ng of total RNA using High Capacity cDNA Reverse Transcription Kit (Applied Biosystems, Foster City, CA). Real-time PCR experiments were performed in 20 µl reaction mixture containing 5 ng of cDNA template, the sequence-specific oligonucleotide primers (purchased from MWG-Biotech AG, Ebersberg, Germany, www.mwg-biotech.com) and the Power SYBR Green PCR Master Mix (Applied Biosystems). Negative cDNA controls (no cDNA) were cycled in parallel with each run. qRT-PCR was performed using a 96-well StepOne™ Real Time System (Applied Biosystems). mRNA comparison between samples was calculated on relative expression data normalized using TATA binding protein (TBP), as endogenous control. Fold change expression with respect to controls was calculated for all samples.
Flow cytometry
For all assays described below, we acquired fluorescence data for 10,000 events on a FACSCalibur flow cytometer (BD Biosciences, Oxford, UK) and analyzed the data with the use of CellQuest software (BD Biosciences) or FlowJo (Treestar). The experiments were repeated at least three times. In some experiments, cells were analyzed on a FACScan (Becton Dickinson, Franklin Lakes, NJ, USA).
Expression of cellular antigens
Expression of cell surface (E-cadherin, CD105, CD133, EpCAM, CD132 (IL-15Rγ), CD29, CD146) and intracellular (OCT-3/4, NANOG, Nestin) proteins was analyzed by flow cytometry as previously described [11, 12] . Briefly, suspensions of enzymaticallyor EDTA-detached cells were permeabilized (for intracytoplasmic staining) or not (for cell surface staining) with BD Cytofix/Cytoperm 5 reagent (BD Pharmingen, Le Pont-De-Claix, France). 5 × 10 5 cells were suspended in DMEM-LG medium supplemented with 1% FCS and stained with conjugated antibodies directed against the above-mentioned cell markers at the dilutions indicated in the "Antibodies, Cytokines, and Reagents" section. Cells were subsequently analyzed by flow cytometry. www.impactjournals.com/oncotarget
ALDH detection
ALDH activity was assessed by flow cytometry in RCC-41-PDX-1/CD132 + and -PDX-2 subsets using ALDEFLUOR kit (StemCell Technologies, Grenoble, France) in accordance with the manufacturer's instructions. Briefly, 10 6 cells from RCC-41-PDX-1/ CD132 + and -PDX-2 subsets were incubated with BODIPY aminoacetaldehyde, which is converted into a fluorescent molecule (BODIPY aminoacetate) in the cytoplasm. Specificity of the fluorescence was shown using the specific ALDH inhibitor diethylaminobenzaldehyde (DEAB).
Tumorigenic potential of RCC-41-PDX-1/ CD132 + and -PDX-2 cells in severe combined immunodeficient (SCID) mice
RCC-41-PDX-1/CD132
+ and -PDX-2 subsets were harvested by incubation with trypsin-EDTA, washed in PBS and resuspended in 100 μL of DMEM. Aliquots of 10 2 or 10 3 cells were added to 100 μL of Matrigel (BD Biosciences), chilled on ice, and injected subcutaneously with a 1-mL syringe fitted with a 26-gauge needle into the left and right sides of 6-week-old male SCID mice (Charles River, Jackson Laboratories, Bar Harbor, ME). Four to eight mice were injected with each of the different RCC-41 subsets. We performed three independent experiments. At different times after cell injections (3, 6, 9, and 10 weeks) the mice were killed by carbon dioxide asphyxiation and their tumors were excised, weighed, and measured. Studies were approved by the Italian 
Immunofluorescence
Indirect immunofluorescence was performed on formalin-fixed, paraffin-embedded tissue sections from 5 xenograft tumors as previously described [47] . Paraffin sections (4 μm thick) were processed by standard deparaffinization with xylene and hydrated in a descending ethanol series to double-distilled water. Antigen retrieval on formalin-fixed tissue section was performed using Sodium-Citrate buffer (pH 6.0). Indirect immunofluorescence was performed using the following primary antibodies: anti-human (h) CD31, monoclonal mouse (diluted 1/100; Dako Cytomation, Hamburg, Germany) and anti-mouse (m) CD34, monoclonal rat (diluted 1:100; Novus Biologicals, Littleton, CO, USA), anti-CD133 (h) (Miltenyi), and anti-EPCAM (h) (Biolegend). Slides were incubated with primary antibodies overnight at 4°C. Secondary antibodies used were: goat anti-mouse IgG Alexa-568 and goat anti-rat IgG Alexa-568 (diluted 1:200; Invitrogen, Germany). After washing, the slides were counterstained with 4′,6′-diamidino-2-phenylindole (DAPI, Sigma-Aldrich, Milan, Italy) and cover-slipped.
The endothelial micro-vessels (EM) were assessed by anti-hCD31 and anti-mCD34 staining and examination of twenty microscopic fields (0.5 mm 2 ) per tumor. The most intense vascular areas (hotspots) were selected subjectively from each tumor section. The micro-vessels with a clearly defined lumen or well-defined linear vessel shape were taken into account.
For image analysis, digital images were collected using a Nikon E-1000 fluorescence microscope (Nikon Instruments, Tokyo, Japan) equipped with appropriate filter sets and the Genikon imaging system software (Nikon Instruments).
Statistical analysis
For tumor studies in mice, the number of animals per group was based on our acquired expertise after 4 years of experiments with this model (we did not perform power calculations to determine the number of mice per group). The unit of analysis was the mouse, and the average of all tumors per mouse was taken into account. For the survival curves, the log rank test was used to compare the survival of the different groups. Otherwise, the two-sided Student's t test was used to compare groups. A P value less than .05 was considered statistically significant. 
